Bluejay Therapeutics is developing monoclonal antibodies targeting chronic viral infections, specifically focusing on chronic hepatitis D and B. The company aims to provide effective treatment options that achieve high virologic response rates, addressing the unmet need for cures in infectious liver diseases.
Funding
$243M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FLFounders
Product
Problem
Chronic viral infections, such as hepatitis D and B, pose significant challenges due to limited effective treatment options and the need for improved virologic response rates. Current therapies often fall short of achieving complete cures, leaving a substantial unmet need in the treatment of infectious liver diseases.
Solution
Bluejay Therapeutics is developing monoclonal antibody therapies specifically designed to target chronic viral infections, with a primary focus on hepatitis D and B. Their approach aims to establish a new standard of care by achieving higher virologic response rates and ultimately providing curative options for patients. The lead monoclonal antibody, BJT-778, has demonstrated promising results, achieving 100% virologic response and up to 78% combined virologic response and ALT normalization as a monotherapy in participants with chronic hepatitis D.
Target Audience
The primary target audience includes patients suffering from chronic hepatitis D and B infections, as well as healthcare providers specializing in infectious diseases and liver diseases.
Features
- Development of monoclonal antibodies targeting specific viral antigens involved in chronic hepatitis D and B infections.
- BJT-778: A lead monoclonal antibody demonstrating best-in-class virologic response in clinical trials for chronic hepatitis D.
- Focus on achieving high rates of virologic response and ALT normalization, key indicators of treatment success.